Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Core Insights - Kiniksa Pharmaceuticals reported a significant increase in net product revenue for ARCALYST, reaching $112.2 million in Q3 2024, which represents a 73% year-over-year growth [1][6] - The company has raised its 2024 expected net product revenue for ARCALYST to between $410 million and $420 million, up from previous guidance [8] - Kiniksa is actively promoting disease awareness for recurrent pericarditis through the Life DisRPted campaign, collaborating with notable figures [3][2] Financial Performance - Total revenue for Q3 2024 was $112.2 million, compared to $67.0 million in Q3 2023 [6] - The net loss for Q3 2024 was $12.7 million, an improvement from a net loss of $13.9 million in Q3 2023 [7] - Total operating expenses for Q3 2024 were $121.9 million, up from $78.0 million in Q3 2023, with collaboration expenses increasing to $29.3 million [6][7] Product and Pipeline Updates - ARCALYST has been prescribed by over 2,550 prescribers since its launch in April 2021, with an average therapy duration of approximately 27 months for recurrent pericarditis [4] - Kiniksa is currently enrolling patients in a Phase 2b clinical trial for abiprubart, targeting Sjögren's Disease [5][2] Strategic Initiatives - The Life DisRPted campaign aims to enhance awareness and early diagnosis of recurrent pericarditis, featuring partnerships with Henrik Lundqvist and Carly Pearce [3] - Kiniksa expects to maintain annual cash flow positivity while continuing to invest in commercialization and pipeline advancement [2][8]